Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C
BMJPublished 20 October 2001Open access
A. Padkin, Kathy Rowan, Nicholas Black
Citations64
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A case study is used to describe the practical difficulties that exist for policymakers and clinicians in interpreting the results of a randomised controlled trial evaluating recombinant human activated protein C, a new drug for treating severe sepsis in intensive care patients, and how an existing, high quality, clinical database could provide information on the generalisability of the trial results.
Keywords
Decision SciencesMedicine
CHEST JournalDefinitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
13,045 Citations1992Roger C. Bone, R.A. Balk +6 more
Broad definitions of sepsis and the systemic inflammatory response syndrome were proposed, along with detailed physiologic parameters by which a patient may be categorized, and the use of severity scoring methods when dealing with septic patients was recommended as an adjunctive tool to assess mortality.
New England Journal of MedicineEfficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
6,122 Citations2001Gordon R. Bernard, Jean‐Louis Vincent +9 more
Treatment with drotrecogin alfa activated significantly reduces mortality in patients with severe sepsis and may be associated with an increased risk of bleeding.
Journal of the American Pharmaceutical Association (Scientific ed )British National Formulary
2,493 Citations1958
The LancetIndications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
2,289 Citations1994Fibrinolytic Therapy Trialists' Collaborative Group
Borås Academic Digital Archive (University of Borås)Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
2,230 Citations1994Johan Herlitz
It is shown that fibrinolytic therapy can reduce mortality in patients with suspected acute myocardial infarction (AMI) and the indications for, and contraindications to, this therapy.
BMJWhy we need observational studies to evaluate the effectiveness of health care
1,602 Citations1996Nicholas Black
The view is widely held that experimental methods (randomised controlled trials) are the "gold standard" for evaluation and that observational methods have little or no value, but this ignores the limitations of randomised trials.
Controlled Clinical TrialsAssessing the quality of randomized controlled trials: An annotated bibliography of scales and checklists
1,304 Citations1995David Moher, Alejandro R. Jadad +4 more
An annotated bibliography of scales and checklists developed to assess quality is presented, giving readers a quantitative index of the likelihood that the reported methodology and results are free of bias.
The LancetSubgroup analysis and other (mis)uses of baseline data in clinical trials
1,159 Citations2000Susan F. Assmann, Stuart Pocock +2 more
Clinical trials need a predefined statistical analysis plan for uses of baseline data, especially covariate-adjusted analyses and subgroup analyses, and investigators and journals need to adopt improved standards of statistical reporting, and exercise caution when drawing conclusions from subgroup findings.
BMJUnderstanding controlled trials: What are pragmatic trials?
706 Citations1998Martín Roland, David Torgerson
The design of a pragmatic trial reflects variations between patients that occur in real clinical practice and aims to inform choices between treatments.
BMJEvidence based policy: proceed with careCommentary: research must be taken seriously
587 Citations2001Nick Black, Alice Donald
Researchers should be cautious about uncritically accepting the notion of evidence based policy, and the implicit assumption of a linear relation between research evidence and policy needs to be replaced with a more interactive model.
The LancetConsequences of discharges from intensive care at night
508 Citations2000Caroline Goldfrad, Kathy Rowan
The implication of these results is that many hospitals have insufficient intensive-care beds and should consider the cost-utility of this particular service compared with other ways that additional resources could be used.
BMJUnlicensed and off label drug use in paediatric wards: prospective study
322 Citations1998S. Turner, Aisling Longworth +2 more
Children in hospital are often treated with drugs not specifically licensed for use in children (unlicensed), and drugs are also used outside the terms of the product licence that apply to indication, age, dose, or route of administration (off label prescribing).
Journal of Health Services Research & PolicyThreats to Applicability of Randomised Trials: Exclusions and Selective Participation
304 Citations1999Annie Britton, Martin McKee +4 more
Narrow inclusion criteria in RCTs may offer benefits such as increased precision and reduced loss to follow-up, but there are important disadvantages, such as uncertainty about extrapolation of results, and delay in obtaining definitive results because of reduced recruitment rate.